Sevenfact Kit
NDC Package 71127-2000-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Sevenfact (coagulation factor viia recombinant human) kits is sEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. Limitation of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency. This formulation utilizes a kit delivery system. Marketed by Laboratoire Fran�ais Du Fractionnement Et Des Biotechnologies Soci�t� Anonyme (lfb S.a.), this product is identified by NDC 71127-2000 and is authorized under FDA application BLA125641.

Identification & Billing

NDC Package Code
71127-2000-1
Package Description
1 KIT in 1 PACKAGE * 2 mL in 1 VIAL, SINGLE-DOSE (71127-2100-1) * 2.2 mL in 1 SYRINGE (71127-2200-1)
Product Code
71127-2000
11-Digit Billing Format
71127200001
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Sevenfact
Non-Proprietary Name
Coagulation Factor Viia Recombinant Human
Dosage Form
Kit - A packaged collection of related material.
Administration Route
Intravenous - Administration within or into a vein or veins.
Usage Information
SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. Limitation of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency.

Regulatory & Marketing

Labeler Name
Laboratoire Fran�ais Du Fractionnement Et Des Biotechnologies Soci�t� Anonyme (lfb S.a.)
Product Type
Human Prescription Drug
FDA Application #
BLA125641
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
03-24-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J7212
Source: ASP
Factor viia recomb sevenfact
HCPCS Dosage 1 MCG
Units / Pkg 2000

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71127-2000-1 identifies a specific commercial package of 1 kit in 1 package * 2 ml in 1 vial, single-dose (71127-2100-1) * 2.2 ml in 1 syringe (71127-2200-1) of Sevenfact, a human prescription drug labeled by Laboratoire Fran�ais Du Fractionnement Et Des Biotechnologies Soci�t� Anonyme (lfb S.a.). This kit is formulated for intravenous use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Laboratoire Fran�ais Du Fractionnement Et Des Biotechnologies Soci�t� Anonyme (lfb S.a.) on March 24, 2025. The current certification is valid through December 31, 2027.

How is this Laboratoire Fran�ais Du Fractionnement Et Des Biotechnologies Soci�t� Anonyme (lfb S.a.) product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71127200001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
71127-2000-1
11-Digit CMS (5-4-2)
71127-2000-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.